Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-Negative Locally Advanced Breast Cancer”

229 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 229 results

Testing effectiveness (Phase 2)Ended earlyNCT04059484
What this trial is testing

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

Who this might be right for
Breast Cancer Metastatic
Sanofi 367
Testing effectiveness (Phase 2)Looking for participantsNCT07486089
What this trial is testing

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

Who this might be right for
Breast Cancer (Locally Advanced or Metastatic)HER2-positive Breast CancerTriple-Negative Breast Cancer (TNBC)
Beijing Biotech 60
Large-scale testing (Phase 3)Active Not RecruitingNCT06635447
What this trial is testing

Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients

Who this might be right for
Breast Cancer
AstraZeneca 293
Large-scale testing (Phase 3)Ended earlyNCT03326674
What this trial is testing

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

Who this might be right for
Breast Cancer
Odonate Therapeutics, Inc. 685
Large-scale testing (Phase 3)Active Not RecruitingNCT04975308
What this trial is testing

Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Who this might be right for
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company 874
Testing effectiveness (Phase 2)WithdrawnNCT03644589
What this trial is testing

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeMetastatic Breast Cancer+3 more
University of Washington
Large-scale testing (Phase 3)Study completedNCT03337724
What this trial is testing

Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 579
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07767474
What this trial is testing

Evaluate ATX-898 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Antares Therapeutics, Inc 343
Not applicableStudy completedNCT05217381
What this trial is testing

Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status

Who this might be right for
Early Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer
MedSIR 18,533
Large-scale testing (Phase 3)UnknownNCT04047758
What this trial is testing

Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

Who this might be right for
Breast Cancer
Shengjing Hospital 420
Testing effectiveness (Phase 2)Study completedNCT03356860
What this trial is testing

Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.

Who this might be right for
Breast CancerTriple Negative Breast CancerLuminal B
Grand Hôpital de Charleroi 57
Early research (Phase 1)WithdrawnNCT01320787
What this trial is testing

18-F-Fluoroacetate as PET Imaging Agent

Who this might be right for
Brain CancerBreast CancerProstate Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)UnknownNCT05403333
What this trial is testing

Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast NeoplasmsLocally Advanced or Metastatic Breast Cancer
Fudan University 61
Large-scale testing (Phase 3)Looking for participantsNCT05860465
What this trial is testing

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd 254
Testing effectiveness (Phase 2)Active Not RecruitingNCT01525966
What this trial is testing

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Who this might be right for
Inflammatory Breast CancerStage IIA Breast CancerStage IIIA Breast Cancer+7 more
City of Hope Medical Center 67
Large-scale testing (Phase 3)Looking for participantsNCT07062965
What this trial is testing

Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Who this might be right for
Breast Cancer
Pfizer 400
Large-scale testing (Phase 3)Looking for participantsNCT07071337
What this trial is testing

SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Who this might be right for
Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 430
Large-scale testing (Phase 3)Ended earlyNCT06038539
What this trial is testing

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Who this might be right for
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Biocon Biologics UK Ltd 55
Testing effectiveness (Phase 2)Study completedNCT02018458
What this trial is testing

Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer

Who this might be right for
Breast Cancer
Baylor Research Institute 10
Testing effectiveness (Phase 2)Study completedNCT02723877
What this trial is testing

PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)

Who this might be right for
Metastatic Breast Cancer
PIQUR Therapeutics AG 41
Next Page